Xenon Pharmaceuticals Inc. Named Company of the Year by BIOTECanada
4/22/2013 10:24:54 AM
More...
|
Xenon Pharmaceuticals Inc. Exclusively Licenses to Merck & Co., Inc. (MRK) Compounds for a Novel Target for Cardiovascular Disease
4/17/2013 8:54:21 AM
More...
|
Xenon Pharmaceuticals Inc. Named Life Sciences Company of the Year by LifeSciences British Columbia
4/8/2013 10:02:21 AM
More...
|
Xenon Pharmaceuticals Inc. Announces Appointment of EVP, Research & Development
2/13/2013 6:40:50 AM
More...
|
Xenon Pharmaceuticals Inc. Receives a Milestone Payment for Marketing Approval of Glybera in Europe
2/5/2013 9:15:41 AM
More...
|
Teva Pharmaceutical Industries Limited (TEVA) Enters $376 Million Deal for Xenon Pharmaceuticals Inc. Pain Drug
12/11/2012 7:47:59 AM
More...
|
Roche (RHHBY) Signs $646 Million Pain Pact With Xenon Pharmaceuticals Inc.
1/9/2012 10:42:53 AM
More...
|
Xenon Pharmaceuticals Inc.'s XEN402 Ointment Significantly Relieves Pain in Patients with Post Herpetic Neuralgia
5/2/2011 9:58:03 AM
More...
|
Xenon Pharmaceuticals Inc. Chief Scientific Officer, Dr. Michael Hayden Receives Prestigious Award for Leadership in Medicine
3/23/2011 7:25:52 AM
More...
|
Isis Pharmaceuticals, Inc. (ISIS) and Xenon Pharmaceuticals Inc. Collaborate to Develop Antisense Drugs Against Hemojuvelin and Hepcidin
11/16/2010 7:02:02 AM
More...
|
|